Blinatumomab for Minimal Residual Disease Clearance in B-Acute Lymphoblastic Leukemia. Annals of Medicine and Medical Sciences, [S. l.], p. 267–272, 2026. DOI: 10.5281/. Disponível em: https://ammspub.com/index.php/amms/article/view/488. Acesso em: 7 mar. 2026.